<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Telomere length and telomerase have an important role in <z:mpath ids='MPATH_458'>normal</z:mpath> and malignant hematopoiesis </plain></SENT>
<SENT sid="1" pm="."><plain>Telomere <z:mpath ids='MPATH_580'>erosion</z:mpath> can lead to chromosome end fusion and thereby contribute to genomic instability during <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Thus, like complex chromosomal aberrations, telomere length may be a prognostic factor in <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A paper by Sieglova et al. in this issue of <z:hpo ids='HP_0001909'>Leukemia</z:hpo> Research reports on the prognostic impact of telomere shortening in bone marrow (BM) and peripheral blood (PB) specimens of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> converted-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients (pts) </plain></SENT>
<SENT sid="4" pm="."><plain>Their results underline the importance to study telomere biology together with cytogenetics, genomic and proteomic profiling as prognostic factors, in order to improve risk-adapted therapy of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> pts </plain></SENT>
</text></document>